Vanguard Group Inc. Has $173.73 Million Stake in BioCryst Pharmaceuticals, Inc. $BCRX

Vanguard Group Inc. grew its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 2.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,273,375 shares of the biotechnology company’s stock after acquiring an additional 482,494 shares during the quarter. Vanguard Group Inc. owned 0.11% of BioCryst Pharmaceuticals worth $173,732,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of BCRX. Royal Bank of Canada raised its stake in BioCryst Pharmaceuticals by 2.4% during the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after acquiring an additional 1,458 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in BioCryst Pharmaceuticals by 6.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company’s stock worth $1,019,000 after acquiring an additional 8,517 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in BioCryst Pharmaceuticals by 49.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock worth $14,490,000 after acquiring an additional 640,704 shares in the last quarter. Caxton Associates LLP acquired a new position in BioCryst Pharmaceuticals during the first quarter worth about $314,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in BioCryst Pharmaceuticals by 11.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company’s stock worth $3,363,000 after acquiring an additional 47,355 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

Insider Buying and Selling at BioCryst Pharmaceuticals

In other news, insider Alane P. Barnes sold 150,000 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $9.15, for a total transaction of $1,372,500.00. Following the sale, the insider directly owned 400,703 shares in the company, valued at approximately $3,666,432.45. The trade was a 27.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 5.10% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on BCRX shares. Royal Bank Of Canada lowered their target price on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Weiss Ratings raised BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research note on Wednesday, March 4th. Wall Street Zen downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday. Needham & Company LLC reduced their price target on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Finally, Wedbush reduced their price target on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $20.70.

BioCryst Pharmaceuticals Stock Performance

NASDAQ:BCRX opened at $8.62 on Monday. The stock has a market cap of $2.19 billion, a P/E ratio of -4.84 and a beta of 0.57. The stock’s 50-day moving average is $9.08 and its 200-day moving average is $7.83. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($3.04). The firm had revenue of $156.41 million for the quarter, compared to the consensus estimate of $151.12 million. BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The business’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.20 earnings per share. As a group, equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post 0.31 EPS for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.